ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Unresectable and/or Metastatic Breast Cancer: Safety Follow-Up of the Phase 3 DESTINY-Breast03

405 views
June 13, 2022
0 Comments
Login to view comments. Click here to Login
Breast